Korenberg Matthew E has filed 42 insider transactions across 3 companies since January 2024.
Most recent transaction: a grant/award of 44123 shares of PALVELLA THERAPEUTICS, INC. ($PVLA) on February 05, 2026.
Activity breakdown: 0 open-market purchases and 13 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 5, 2026 | PALVELLA THERAPEUTICS, INC. | $PVLA | Korenberg Matthew E | CFO, Treasurer | A | Stock Option (Right to Buy) | 44123 | $0.00 | 44,123.0000 | 11,836,490 | 9999.99% | 0.37% |
| July 15, 2025 | LIFECORE BIOMEDICAL, INC. DE | $LFCR | Korenberg Matthew E | Director | A | Common Stock | 19506 | $0.00 | 44,060.0000 | 0 | 79.44% | 0.00% |
| Feb. 5, 2025 | PALVELLA THERAPEUTICS, INC. | $PVLA | Korenberg Matthew E | CFO and Treasurer | A | Non-Qualified Stock Option (right to buy) | 123559 | $0.00 | 123,559.0000 | 0 | 9999.99% | 0.00% |
| Feb. 5, 2025 | PALVELLA THERAPEUTICS, INC. | $PVLA | Korenberg Matthew E | CFO and Treasurer | A | Incentive Stock Option (right to buy) | 5373 | $0.00 | 5,373.0000 | 0 | 9999.99% | 0.00% |
| Dec. 13, 2024 | PALVELLA THERAPEUTICS, INC. | $PVLA | Korenberg Matthew E | CFO, Treasurer | A | Stock Option (right to buy) | 167100 | $0.00 | 167,100.0000 | 0 | 9999.99% | 0.00% |
| Sept. 20, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Korenberg Matthew E | President & COO | S | Common Stock | 6275 | $104.10 | 50,777.0000 | 17,757,000 | 11.00% | 0.04% |
| Sept. 23, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Korenberg Matthew E | President & COO | M | Common Stock | 395 | $49.99 | 51,172.0000 | 17,757,000 | 0.78% | 0.00% |
| Sept. 23, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Korenberg Matthew E | President & COO | M | Common Stock | 9377 | $52.84 | 60,549.0000 | 17,757,000 | 18.32% | 0.05% |
| Sept. 23, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Korenberg Matthew E | President & COO | S | Common Stock | 2481 | $100.05 | 58,068.0000 | 17,757,000 | 4.10% | 0.01% |
| Sept. 23, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Korenberg Matthew E | President & COO | S | Common Stock | 201 | $102.05 | 50,777.0000 | 17,757,000 | 0.39% | 0.00% |
| Sept. 23, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Korenberg Matthew E | President & COO | S | Common Stock | 7090 | $101.61 | 50,978.0000 | 17,757,000 | 12.21% | 0.04% |
| Sept. 20, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Korenberg Matthew E | President & COO | M | Common Stock | 4982 | $49.99 | 57,052.0000 | 17,757,000 | 9.57% | 0.03% |
| Sept. 20, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Korenberg Matthew E | President & COO | M | Employee Stock Option (right to buy) | 4982 | $0.00 | 395.0000 | 17,757,000 | 92.65% | 0.03% |
| Sept. 23, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Korenberg Matthew E | President & COO | M | Employee Stock Option (right to buy) | 395 | $0.00 | 0.0000 | 17,757,000 | 100.00% | 0.00% |
| Sept. 23, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Korenberg Matthew E | President & COO | M | Employee Stock Option (right to buy) | 9377 | $0.00 | 42,436.0000 | 17,757,000 | 18.10% | 0.05% |
| Sept. 16, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Korenberg Matthew E | President & COO | M | Common Stock | 3340 | $60.94 | 54,008.0000 | 17,757,000 | 6.59% | 0.02% |
| Sept. 16, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Korenberg Matthew E | President & COO | M | Common Stock | 914 | $55.75 | 50,424.0000 | 17,757,000 | 1.85% | 0.01% |
| Sept. 16, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Korenberg Matthew E | President & COO | F | Common Stock | 485 | $105.00 | 49,939.0000 | 17,757,000 | 0.96% | 0.00% |
| Sept. 16, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Korenberg Matthew E | President & COO | M | Common Stock | 849 | $58.49 | 50,788.0000 | 17,757,000 | 1.70% | 0.00% |
| Sept. 16, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Korenberg Matthew E | President & COO | F | Common Stock | 472 | $105.00 | 50,316.0000 | 17,757,000 | 0.93% | 0.00% |
| Sept. 16, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Korenberg Matthew E | President & COO | M | Common Stock | 671 | $49.99 | 50,987.0000 | 17,757,000 | 1.33% | 0.00% |
| Sept. 16, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Korenberg Matthew E | President & COO | F | Common Stock | 319 | $105.00 | 50,668.0000 | 17,757,000 | 0.63% | 0.00% |
| Sept. 16, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Korenberg Matthew E | President & COO | F | Common Stock | 1938 | $105.00 | 52,070.0000 | 17,757,000 | 3.59% | 0.01% |
| Sept. 16, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Korenberg Matthew E | President & COO | M | Employee Stock Option (right to buy) | 671 | $0.00 | 5,377.0000 | 17,757,000 | 11.09% | 0.00% |
| Sept. 16, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Korenberg Matthew E | President & COO | M | Employee Stock Option (right to buy) | 914 | $0.00 | 25,949.0000 | 17,757,000 | 3.40% | 0.01% |
| Sept. 16, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Korenberg Matthew E | President & COO | M | Employee Stock Option (right to buy) | 849 | $0.00 | 12,452.0000 | 17,757,000 | 6.38% | 0.00% |
| Sept. 16, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Korenberg Matthew E | President & COO | M | Employee Stock Option (right to buy) | 3340 | $0.00 | 18,500.0000 | 17,757,000 | 15.29% | 0.02% |
| Aug. 26, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Korenberg Matthew E | President & COO | S | Common Stock | 5212 | $106.32 | 49,510.0000 | 17,757,000 | 9.52% | 0.03% |
| Aug. 22, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Korenberg Matthew E | President & COO | S | Common Stock | 1157 | $105.54 | 67,211.0000 | 17,757,000 | 1.69% | 0.01% |
| Aug. 23, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Korenberg Matthew E | President & COO | S | Common Stock | 2037 | $104.09 | 65,174.0000 | 17,757,000 | 3.03% | 0.01% |
| Aug. 23, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Korenberg Matthew E | President & COO | S | Common Stock | 4275 | $105.13 | 60,899.0000 | 17,757,000 | 6.56% | 0.02% |
| Aug. 26, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Korenberg Matthew E | President & COO | S | Common Stock | 6177 | $105.02 | 54,722.0000 | 17,757,000 | 10.14% | 0.03% |
| Aug. 19, 2024 | LIFECORE BIOMEDICAL, INC. DE | $LFCR | Korenberg Matthew E | Director | A | Common Stock | 24554 | $0.00 | 24,554.0000 | 0 | 9999.99% | 0.00% |
| Aug. 9, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Korenberg Matthew E | President & COO | S | Common Stock | 18245 | $98.50 | 68,368.0000 | 17,757,000 | 21.06% | 0.10% |
| June 28, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Korenberg Matthew E | President & Chief Operating | J | Common Stock | 350 | $60.71 | 86,613.0000 | 17,757,000 | 0.41% | 0.00% |
| May 14, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Korenberg Matthew E | President & Chief Operating | S | Common Stock | 520 | $85.68 | 86,263.0000 | 17,757,000 | 0.60% | 0.00% |
| May 14, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Korenberg Matthew E | President & Chief Operating | S | Common Stock | 13638 | $85.08 | 86,783.0000 | 17,757,000 | 13.58% | 0.08% |
| May 13, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Korenberg Matthew E | President & Chief Operating | S | Common Stock | 3440 | $84.54 | 100,421.0000 | 17,757,000 | 3.31% | 0.02% |
| Feb. 27, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Korenberg Matthew E | PRESIDENT & CHIEF OPERATING | A | Employee Stock Option (right to buy) | 58544 | $0.00 | 58,544.0000 | 17,757,000 | 9999.99% | 0.33% |
| Feb. 27, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Korenberg Matthew E | PRESIDENT & CHIEF OPERATING | A | Common Stock | 14416 | $0.00 | 103,861.0000 | 17,757,000 | 16.12% | 0.08% |
| Feb. 15, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Korenberg Matthew E | PRESIDENT & CHIEF OPERATING | F | Common Stock | 4778 | $74.65 | 89,445.0000 | 17,757,000 | 5.07% | 0.03% |
| Jan. 2, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Korenberg Matthew E | PRESIDENT & CHIEF OPERATING | F | Common Stock | 2917 | $72.31 | 94,223.0000 | 17,757,000 | 3.00% | 0.02% |